Disease · MONDO_0005161

human papilloma virus infection

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. human papilloma virus infection. Diseases, record MONDO_0005161. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005161

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: human papilloma virus infection; Open Targets
Open Targets ID: MONDO_0005161; Open Targets
Other names: HPV, HPV infection, Human Papillomavirus infection, Human papillomavirus caused disease or disorder, Human papillomavirus disease or disorder; Open Targets
Disease Ontology: DOID:11166; Disease Ontology
MeSH: D030361; MeSH
NCI Thesaurus: C27851; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 26 drugs, from TTD; Open Targets

Drugs26

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLES	CHEMBL6068359	Vaccine component	Approval	TTD	8	5	1	Drugs and targets
VERPASEP CALTESPEN	CHEMBL2108664		Phase 3	TTD	1	0	0	Drugs and targets
INTERFERON ALFA-2B	CHEMBL1201558	Protein	Phase 2/3	ClinicalTrials.gov	3	3	0	Drugs and targets
NOVAFERON	CHEMBL4650410		Phase 2/3	ClinicalTrials.gov	3	3	0	Drugs and targets
PEGINTERFERON ALFA-2B	CHEMBL1201561	Protein	Phase 2/3	ClinicalTrials.gov	3	3	0	Drugs and targets
ROPEGINTERFERON ALFA-2B	CHEMBL4297819	Protein	Phase 2/3	ClinicalTrials.gov	3	3	0	Drugs and targets
IMIQUIMOD	CHEMBL1282	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
EPIGALOCATECHIN GALLATE	CHEMBL297453	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ARTESUNATE	CHEMBL361497	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 26

See all 26 drugs

Targets21

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
IFNAR1	Interferon alpha/beta receptor	3	Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulator	Phase 2/3	https://conductscience.org/library/genes/3454	Drugs and targets
IFNAR2	Interferon alpha/beta receptor	3	Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulator	Phase 2/3	https://conductscience.org/library/genes/3455	Drugs and targets
FNTA	Protein farnesyltransferase	1	Protein farnesyltransferase inhibitor	Phase 2	https://conductscience.org/library/genes/2339	Drugs and targets
FNTB	Protein farnesyltransferase	1	Protein farnesyltransferase inhibitor	Phase 2	https://conductscience.org/library/genes/2342	Drugs and targets
TLR7	Toll-like receptor 7	1	Toll-like receptor 7 agonist	Phase 2/3	https://conductscience.org/library/genes/51284	Drugs and targets
TUBA1A	Tubulin	1	Tubulin inhibitor	Phase 1	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	1	Tubulin inhibitor	Phase 1	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	1	Tubulin inhibitor	Phase 1	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	1	Tubulin inhibitor	Phase 1	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	1	Tubulin inhibitor	Phase 1	https://conductscience.org/library/genes/112714	Drugs and targets

1 to 10 of 21

See all 21 targets

Trials12

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 6 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02864147	Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)	Phase 2	134	2024-05-02	Cervical Intraepithelial Neoplasia, Cervical Dysplasia	IMIQUIMOD	Its record names the disease	ClinicalTrials.gov
NCT05413811	Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living With HIV	Not applicable	180		Cervical Cancer, CIN2, CIN3, Human Immunodeficiency Virus, Human Papillomavirus	FLUOROURACIL	Its record names the disease	ClinicalTrials.gov
NCT06098456	Epigallocatechin Gallate and Other Antural Compounds in HPV Infections	Phase 2	178		Papilloma-induced Cervical Lesions	EPIGALOCATECHIN GALLATE, FOLIC ACID, HYALURONIC ACID, VITAMIN B12	Its record names the disease	ClinicalTrials.gov
NCT07545746	Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya	Phase 2	140		HIV Infections, HPV Infection, Cervix Cancer, CIN2, CIN3, CIN1, CIN, Cervical Intraepithelial Neoplasia Grade 3, Cervical Intraepithelial Neoplasia Grade 1, Cervical Intraepithelial Neoplasia Grade 2/3	FLUOROURACIL	Its record names the disease	ClinicalTrials.gov
NCT06519994	Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya	Phase 2	120		Human Immunodeficiency Virus, Human Papillomavirus, Cervical Precancer	ARTESUNATE	Its record names the disease	ClinicalTrials.gov
NCT00941252	ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial	Phase 2/3	60		Cervical Intraepithelial Neoplasia	IMIQUIMOD	Its record names the disease	ClinicalTrials.gov
NCT02263378	A New Supplement for the Immune Response to HPV Infection	Not applicable	60		HPV Infection	ELLAGIC ACID	Its record names the disease	ClinicalTrials.gov
NCT04572100	Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer	Phase 1	50		Oropharyngeal Squamous Cell Carcinoma	CARBOPLATIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT07407569	Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination	Phase 2	50		Human Papilloma Virus Infection Type 16	HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLES	Its record names the disease	ClinicalTrials.gov
NCT07572396	Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities	Phase 2	45		High-risk HPV (Any Strain), LSIL, Low Grade Squamous Intraepithelial Lesion, ASC-US, HPV Infection, Cervical Abnormalities, Uterine Cervical Dysplasia	EPIGALOCATECHIN GALLATE, QUININE SULFATE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 12

See all 12 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials7

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41891028	DERIVED	1	PubMed
41890998	DERIVED	1	PubMed
41780745	DERIVED	1	PubMed
40907021	DERIVED	1	PubMed
40832398	DERIVED	1	PubMed
34980038	DERIVED	1	PubMed
22914404	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005161

GET https://conductscience.org/api/diseases/v1/MONDO_0005161/drugs?page=2

API reference For AI assistants